Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

Chronic Myelomonocytic Leukemia Clinical Trial

Official title:

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of Mutation TP53 (TP53) Mutant Myeloid Neoplasms

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03588078
• Other study ID #: GFM-APR246
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: September 15, 2018
• Est. completion date: May 15, 2021

Study information

• Verified date: January 2020
• Source: Groupe Francophone des Myelodysplasies
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to determine the safe and efficacy of APR-246 in combination with azacitidine as well as to see complete remission of this patients

Description:

Patients will be treated for a total of 6 cycles.For patients responding or who have stable disease following cycle 6, treatment may continue until one of the following criteria applies:

• Inter-current illness that prevent further administration of treatment

• Unacceptable adverse event(s)

• Participant decides to withdraw from the study,

• general or specific changes in the participant's condition render the participant unacceptable for further treatment in the judgment of the investigator.

• Evidence of disease progression by international working Group (IWG) 2006 criteria.

• participants who wish not to continue treatment at time of disease assessment at end of cycle 6 will complete their end of treatment visit upon completion of cycle 6

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 53
• Est. completion date: May 15, 2021
• Est. primary completion date: May 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient has signed the Informed Consent (ICF) and is able to comply with protocol requirements.

2. Patient has adequate organ function as defined by the following laboratory values:

1. Serum creatinine = 2 x upper limit of normal (ULN)

2. Total serum bilirubin < 1.5 x ULN or total bilirubin = 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert's Syndrome or hemolysis or who required regular blood transfusions

3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN

3. Age =18 years at the time of signing the informed consent form

4. Documented diagnosis of myelodysplastic syndrome (MDS), MDS/ myeloproliferative neoplasm (MPN), chronic myelomonocytic leukemia (CMML) by World Health organization (WHO) criteria or non-proliferative AML (ie with WBC < 20 G/l)

5. Documentation of a TP53 gene mutation by next-generation sequencing (NGS) based on central or local evaluation.

6. Revised International Prognostic Scoring System (IPSS-R) criteria for Intermediate, High-risk or Very High-risk.

7. An Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 is required.

8. If of childbearing potential, negative pre-treatment urine or serum pregnancy test.

9. If of childbearing potential (males and females), willing to use an effective form of contraception such as latex condom, hormonal birth control, intrauterine device or double barrier method during chemotherapy treatment and for at least six months thereafter.

Exclusion Criteria:

1. Patient has a known history of HIV or active hepatitis B or active hepatitis C infection (testing not mandatory).

2. Patient has any of the following cardiac abnormalities (as determined by treating MD):

1. symptomatic congestive heart failure

2. myocardial infarction = 6 months prior to enrollment

3. unstable angina pectoris

4. serious uncontrolled cardiac arrhythmia

5. QTc = 470 msec (= 500 msec in the presence of RBBB) calculated from a mean of 3 ECG readings using Fridericia's correction (QTcF = QT/RR0.33)

6. bradycardia (<40 bpm)

7. known left ventricular ejection fraction (LVEF) < the institution lower limit of normal as assessed by ECHO

8. clinically significant pericardial disease

9. electrocardiographic evidence of acute ischemia

10. familial history of long QT syndrome

3. Concomitant malignancies or previous malignancies with less than a 1-year disease free interval at the time of signing consent. Patients with adequately resected basal or squamous cell carcinoma of the skin, or adequately resected carcinoma in situ (e.g. cervix) may enroll irrespective of the time of diagnosis.

4. Prior exposure to azacitidine, decitabine or investigational hypomethylating agent

5. Use of cytotoxic chemotherapeutic agents, or experimental agents (agents that are not commercially available) for the treatment of MDS, MDS/MPN, CMML or AML within 14 days of the first day of study drug treatment.

6. No concurrent use of erythroid stimulating agents, Granulocyte-colony stimulating Factor (G-CSF), Granulocyte Macrophage-colony stimulating factor (GM-CSF) is allowed during study except in cases of febrile neutropenia where G-CSF can be used for short term. Growth factors must be stopped 14 days prior to study.

7. Patients with history of allogeneic stem cell transplantation.

8. Pregnant women are excluded from this study because APR-246 has not been studied in pregnant subjects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with APR-246, breastfeeding should be discontinued if the mother is treated with APR-246.

Related Conditions & MeSH terms

• Acute Myeloid Leukemia With Gene Mutations
• Chronic Myelomonocytic Leukemia
• Leukemia
• Leukemia, Myelomonocytic, Chronic
• Leukemia, Myelomonocytic, Juvenile
• Myelodysplastic Syndrome With Gene Mutation
• Myelodysplastic Syndromes
• Myeloproliferative Disorders
• Myeloproliferative Neoplasm
• Neoplasms

Intervention

Drug:
• APR-246
Azacitidine at maximum tolerated dose. APR246 at the Dose limited Toxicity (DLT) dose
• Azacitidine
azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m2

Locations

Country	Name	City	State
France	Bruno Quesnel	Lille
France	Dr Pierre Peterlin and Pr Patrice Chevalier	Nantes
France	Hôpital Archet 1	Nice
France	Hôpital Cochin/Service d'Hématologie	Paris
France	Hôpital Saint Louis - Hématologie Séniors	Paris
France	Aspasia Stamatoullas	Rouen
France	Odile Beyne Rosy	Toulouse

Sponsors (2)

Lead Sponsor	Collaborator
Groupe Francophone des Myelodysplasies	Aprea Therapeutics AB

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival	overall survival at complete remission	8 months
Secondary	Duration of response		minimum 24 months it is defined as the time between achieving response and progression of disease